1. Home
  2. TNGX vs IRS Comparison

TNGX vs IRS Comparison

Compare TNGX & IRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tango Therapeutics Inc.

TNGX

Tango Therapeutics Inc.

HOLD

Current Price

$10.77

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)

IRS

IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)

HOLD

Current Price

$15.28

Market Cap

1.2B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNGX
IRS
Founded
2014
1943
Country
United States
Argentina
Employees
155
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
N/A
1994

Fundamental Metrics

Financial Performance
Metric
TNGX
IRS
Price
$10.77
$15.28
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$12.00
N/A
AVG Volume (30 Days)
3.1M
201.8K
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
9.12%
EPS Growth
N/A
N/A
EPS
N/A
0.42
Revenue
$66,501,000.00
$370,153,377.00
Revenue This Year
$20.41
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$3.48
Revenue Growth
53.29
N/A
52 Week Low
$1.03
$10.61
52 Week High
$11.20
$17.67

Technical Indicators

Market Signals
Indicator
TNGX
IRS
Relative Strength Index (RSI) 74.54 53.65
Support Level $9.90 $13.89
Resistance Level $11.20 $17.21
Average True Range (ATR) 0.72 0.83
MACD 0.31 -0.21
Stochastic Oscillator 89.35 41.87

Price Performance

Historical Comparison
TNGX
IRS

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)

IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segments include Shopping Malls, which comprise lease and service revenues principally related to the rental of commercial and other spaces in the company's shopping malls; Offices, which include lease revenues and other service revenues related to office activities; Sales and Developments, which include the development, maintenance, and sales of undeveloped parcels of land and/or trading properties; Hotels, which mainly include revenues from rooms, catering, and restaurants; and others. The company generates the majority of its revenue from the Shopping Malls segment.

Share on Social Networks: